Skip to main content

Sensitizing EGFR Gene Mutation clinical trials at UC Irvine

1 in progress, 0 open to eligible people

Showing trials for
  • A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

    Sorry, not currently recruiting here

    This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).

    Irvine, California and other locations

Last updated: